Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

This was the stock's third consecutive day of losses.

Consumer discretionary stocks are at the forefront of the retail and leisure sectors, driven by robust consumer spending ...

Born in Mumbai, Reshma moved to the United States at the age of 11. She earned her medical degree from Boston University and ...

VRTX eyes second-quarter growth with surging Trikafta sales. Investors' focus is likely to be on the progress of Casgevy, and ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

Some Boston public school students are spending their summer vacations learning and working at a global biotech company.

Frazier was among the most active venture investors in 2024, according to analysts at William Blair, backing 17 private life ...

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...

Vertex Pharmaceuticals (VRTX) closed at $468.41 in the latest trading session, marking a +1.64% move from the prior day. This change outpaced the S&P 500's 0.3% loss on the day. Meanwhile, the Dow ...

U.S. equities rebounded strongly in Q2, with growth stocks and mid-caps leading gains; our portfolio outperformed via IT, ...

Franklin Templeton shares Q2 2025 results for ClearBridge All Cap Growth Portfolios: tech wins offset health care drag. See ...